Executive Summary: Solving the Targeted Chemotherapy and High-Potency Payload Delivery Challenge
Medical oncologists and patients face a critical treatment challenge: delivering highly cytotoxic chemotherapy agents directly to cancer cells while minimizing systemic toxicity (neutropenia, neuropathy, alopecia, cardiotoxicity, nausea/vomiting) associated with conventional chemotherapy (anthracyclines, taxanes, platinum agents). Antibody-drug conjugates (ADCs) address this need via a monoclonal antibody linked to a cytotoxic payload (drug-to-antibody ratio typically 2-8). ADC drugs have gradually become a hot spot in anti-tumor treatment research due to advantages of high efficacy (selective cancer cell killing, bystander effect) and lower systemic toxicity (reduced off-target exposure), revolutionizing treatment for HER2-positive breast cancer, CD30-positive lymphoma, HER2-low breast cancer, Nectin-4-positive urothelial cancer, TROP-2-positive triple-negative breast cancer, and many others. This deep-dive analyzes DNA damaging payloads (calicheamicin, DXd) vs. tubulin inhibitors (MMAE, DM1, DM4) across breast cancer, lymphoma, and other solid tumors.
The global market for antitumor ADC drugs was valued at US8,450millionin2025,projectedtoreachUS8,450millionin2025,projectedtoreachUS 24,200 million by 2032, growing at a staggering CAGR of 16.2% from 2026 to 2032 — one of the fastest-growing oncology segments. Growth driven by label expansions (HER2-low breast cancer, 2022), new approvals (Enhertu, Trodelvy, Padcev, Zynlonta, Blenrep, Elahere), and first-line therapy adoption.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5975929/antitumor-adc-drugs
1. Core ADC Components and Payload Families
ADC efficacy depends on antibody specificity, linker stability, and payload potency:
| Payload Class | Mechanism | Representative ADCs | Tumor Types | Key Advantages | Bystander Effect |
|---|---|---|---|---|---|
| DNA Damaging Agents | DNA crosslinking, topoisomerase I inhibition | Trastuzumab deruxtecan (Enhertu, HER2), sacituzumab govitecan (Trodelvy, TROP-2), datopotamab deruxtecan (Dato-DXd, TROP-2, NDA) | HER2+ breast, HER2-low breast, TNBC, NSCLC, urothelial | High potency, cleavable linker, membrane-permeable payload, strong bystander effect | Yes (DXd) |
| Tubulin Inhibitors (Maytansinoids) | Microtubule disruption (mitotic arrest, apoptosis) | Trastuzumab emtansine (Kadcyla, T-DM1), mirvetuximab soravtansine (Elahere, FRα), denintuzumab mafodotin | HER2+ breast (adjuvant, metastatic), ovarian, DLBCL | Non-permeable payload (limited bystander), stable linker, good tolerability | Limited (DM1/DM4) |
| Tubulin Inhibitors (Auristatins) | Microtubule inhibition (anti-mitotic) | Brentuximab vedotin (Adcetris, CD30, MMAE), enfortumab vedotin (Padcev, Nectin-4), polatuzumab vedotin (Polivy, CD79b), tisotumab vedotin (Tivdak, tissue factor) | HL, ALCL, PTCL, DLBCL, urothelial, cervical | Membrane-permeable payload, strong bystander effect, cleavable linker, high DAR (4-8), MMAE potency | Yes (MMAE) |
独家观察 (Exclusive Insight): While trastuzumab deruxtecan (Enhertu, DS-8201, Daiichi Sankyo/AstraZeneca) redefined HER2-positive (and now HER2-low) breast cancer, the future of ADC differentiation is in novel payloads beyond tubulin inhibitors/DNA damaging agents (TOP1 inhibitors, novel anti-mitotics, immunotherapy ADC). A January 2026 ASCO plenary reported datopotamab deruxtecan (Dato-DXd, TROP-2 ADC, DXd payload) phase 3 TROPION-Breast01 met PFS endpoint (6.9 vs. 4.9 months) in HR+/HER2- breast cancer, poised to compete with sacituzumab govitecan (SG). Additionally, emerging dual-payload ADCs (two distinct payloads, e.g., HER2-targeting trastuzumab with both MMAE + camptothecin analog, bispecific ADCs, immune-stimulating ADCs) are entering phase 1/2. Mersana’s XMT-2056 (STING agonist ADC) phase 1 data showed early immunogenicity. ADC deal activity: >20 licensing/acquisitions 2024-2025 (Merck-Synaffix (2B),AbbVie−ImmunoGen(2B),AbbVie−ImmunoGen(10B), Pfizer-Seagen ($43B) influencing pipeline. The FDA approved 12 ADCs by 2025 (Adcetris 2011, Kadcyla 2013, Enhertu 2019, Padcev 2019, Trodelvy 2020, Blenrep 2020-2022 withdrawn, Zynlonta 2021, Elahere 2022, Tivdak 2022, Polivy 2019). Project 50+ ADCs in phase 3 by 2028.
2. Segmentation by Payload Type & Application
| Segment | 2025 Market Share (Value) | Key ADCs | Primary Tumor Indications | Bystander Effect |
|---|---|---|---|---|
| DNA Damaging (DXd, Calicheamicin) | 55% (Enhertu 4.2B,Trodelvy4.2B,Trodelvy1.1B, Dato-DXd $0.2B) | Enhertu (HER2), Trodelvy (TROP-2), Besponsa (CD22, calicheamicin) | HER2+ breast, HER2-low breast, TNBC, NSCLC, gastric, colorectal | Yes (DXd, key) |
| Tubulin Inhibitors (Auristatin MMAE) | 35% | Adcetris (CD30), Padcev (Nectin-4), Polivy (CD79b), Tivdak (TF) | HL, ALCL, PTCL, DLBCL, urothelial, cervical | Yes (MMAE) |
| Tubulin Inhibitors (Maytansinoids DM1/DM4) | 10% | Kadcyla (HER2), Elahere (FRα), IMGN-151, SAR408701 | HER2+ breast (adjuvant), ovarian | Limited (DM1) |
3. Application Analysis: Breast Cancer vs. Lymphoma vs. Other Solid Tumors
Breast Cancer (HER2+, HER2-low) (50% of ADC market): Largest segment. Enhertu (HER2) captured first-line HER2+ (DESTINY-Breast03, PFS 28.8 vs. 6.8 mos vs. T-DM1) and HER2-low (DESTINY-Breast04, 2.9 mos PFS advantage). Trodelvy (TROP-2) for TNBC (ASCENT trial). Dato-DXd (TROP-2) HR+/HER2- filing 2025, approval 2026. Requirement: HER2 testing (IHC 1+, 2+ FISH negative) for HER2-low indication; TROP-2 expression required? No.
Lymphoma (Hodgkin/ALCL/PTCL/DLBCL) (20% share): Adcetris (CD30-MMAE) standard for HL after BV-AVD (2024 FDA). Polivy (CD79b-MMAE) plus BR for DLBCL. Zynlonta (CD19, loncastuximab tesirine, DNA payload) for R/R DLBCL. Requirement: CD30 IHC for BV.
Other Solid Tumors (Urothelial, Cervical, Ovarian, NSCLC, Gastric) (30%): Padcev (Nectin-4-MMAE) first-line (cisplatin-ineligible) plus pembrolizumab (FDA 2023). Tivdak (TF-MMAE) for cervical cancer (2L). Elahere (FRα-DM4) for ovarian (Phase 3). Requirement: biomarker testing (Nectin-4, TF, FRα).
4. Competitive Landscape and Manufacturing Challenges
Key Suppliers: Seattle Genetics (Seagen, Pfizer acquisition) — Adcetris, Padcev, Tukysa, Tivdak, led ADC field; Roche/Kadcyla, Polivy; Daiichi Sankyo/AstraZeneca — Enhertu, Dato-DXd (TROP-2), DS-7300 (B7-H3); Immunomedics (Gilead) — Trodelvy; ADC Therapeutics — Zynlonta; RemeGen (China) — RC48 (HER2, approved in China for gastric/breast); Genmab — partnered with Seagen; GSK — Blenrep (BCMA, withdrawn 2022, re-evaluating); Rakuten Medical (ill-defined, not ADC).
Challenges: Manufacturing complexity — conjugation (random vs. site-specific), DAR distribution, stability (aggregation). High cost of goods (COGs $5,000-10,000/g antibody). Resistance mechanisms — target downregulation, payload efflux (MDR), impaired internalization, lysosomal dysfunction. Toxicity — interstitial lung disease (Enhertu 10-15%), peripheral neuropathy (MMAE-class), ocular toxicity (Elahere), thrombocytopenia.
5. Forecast and Strategic Recommendations (2026–2032)
| Metric | 2025 Actual | 2032 Projected | CAGR |
|---|---|---|---|
| Global market value | $8,450M | $24,200M | 16.2% |
| Breast cancer share (HER2+) | 50% | 40% | — |
| Non-breast solid tumors share (urothelial, NSCLC, gastric) | 20% | 35% | 22% |
| Novel payload (non-tubulin/non-DNA) share | <1% | 10% | 35% |
| Asia-Pacific market share | 10% | 20% | 20% |
- Fastest-growing region: Asia-Pacific (CAGR ~20%), China (Enhertu approval 2023, RC48 local, NRDL reimbursement, 15 approved ADCs by 2025).
- Fastest-growing segment: Non-HER2 ADCs (TROP-2, Nectin-4, FRα, B7-H3, HER3, CEACAM5, etc.) for solid tumors beyond breast.
- Price trends: Established ADCs (Kadcyla, Adcetris) pricing 6,000−12,000/month,genericrisklowduetobiologiccomplexity.NewerADCspremiumpricing6,000−12,000/month,genericrisklowduetobiologiccomplexity.NewerADCspremiumpricing12,000-18,000/month.
Conclusion: ADCs have transformed oncology, with Enhertu and Trodelvy expanding chemotherapy target space. Global Info Research recommends oncologists use HER2 testing (IHC 0 to 3+) and HER2-low classification for breast cancer; consider TROP-2 ADCs (Trodelvy, Dato-DXd) for TNBC/HR+; administer MMAE-class ADCs (Adcetris, Padcev) with close monitoring (neuropathy, rash). As payload diversity expands to TOP1 inhibitors, dual-payload, and immune-stimulating ADCs, the class will continue rapid growth.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
